The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
 
Kevin Kalinsky
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Honoraria - Amgen; AstraZeneca; Immunomedics; pfizer
 
Sandra J. Lee
No Relationships to Disclose
 
Krista M. Rubin
No Relationships to Disclose
 
Donald P. Lawrence
No Relationships to Disclose
 
A. John Iafrate
Stock and Other Ownership Interests - Archer
Consulting or Advisory Role - Chugai Pharma; Constellation Pharmaceuticals; Debiopharm Group
Research Funding - Blueprint Medicines
Patents, Royalties, Other Intellectual Property - ArcherDx exclusive license to AMP technology
 
Darrell R. Borger
No Relationships to Disclose
 
Kim Allyson Margolin
Honoraria - Bristol-Myers Squibb; Genentech/ROche
Consulting or Advisory Role - Amgen; Inanovate; Nektar; NeoStem; Oncosec; Prothena
Research Funding - Altor Bioscience; Bristol-Myers Squibb
 
Mario M. Leitao
No Relationships to Disclose
 
Henry B. Koon
No Relationships to Disclose
 
Ahmad A. Tarhini
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Prometheus
 
Andrew Pecora
No Relationships to Disclose
 
Gary Irvin Cohen
Stock and Other Ownership Interests - Abbvie; Celgene; Foundation Medicine; Nymox
Consulting or Advisory Role - Eviti
Research Funding - Amgen (Inst); Celgene (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst)
 
Timothy Kuzel
Honoraria - Amgen; Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Bionomics; Celgene; Eisai; Genentech/Roche; Janssen
Speakers' Bureau - Astellas Pharma; Bayer; Celgene; Genentech/Roche; Janssen Oncology
Research Funding - Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); CureTech (Inst); Eisai (Inst); Genentech/Roche (Inst); MedImmune (Inst); Merck/Schering Plough (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Celgene; elorac; Genentech; Janssen Oncology
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; GreenPeptide; Roche
Research Funding - Merck (Inst); Prometheus (Inst)